Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

被引：0
|
作者：
Nikolaos Xenidis
Nikolaos Vardakis
Ioannis Varthalitis
Stylianos Giassas
Emmanouel Kontopodis
Nikolaos Ziras
Ioannis Gioulbasanis
George Samonis
Kostas Kalbakis
Vassilis Georgoulias
机构：
[1] University General Hospital of Alexandroupolis,Department of Medical Oncology
[2] University General Hospital of Heraklion,Department of Medical Oncology
[3] “Agios Georgios” General Hospital of Chania,Department of Medical Oncology
[4] “IASO” General Hospital of Athens,Department of Medical Oncology
[5] “METAXA” Anticancer Hospital of Piraeus,Department of Medical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Pegylated doxorubicin; CPT-11; SCLC; Second-line treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 68
页数：5
相关论文
共 50 条
  • [21] A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small-cell lung cancer (SCLC).
    Negoro, S
    Uejima, H
    Takeda, K
    Miyazaki, M
    Takihuji, N
    Hirashima, T
    Matsui, K
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [22] Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
    Koinis, F.
    Agelaki, S.
    Karavassilis, V.
    Kentepozidis, N.
    Samantas, E.
    Peroukidis, S.
    Katsaounis, P.
    Hartabilas, E.
    Varthalitis, I. I.
    Messaritakis, I.
    Fountzilas, G.
    Georgoulias, V.
    Kotsakis, A.
    BRITISH JOURNAL OF CANCER, 2017, 117 (01) : 8 - 14
  • [23] Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
    F Koinis
    S Agelaki
    V Karavassilis
    N Kentepozidis
    E Samantas
    S Peroukidis
    P Katsaounis
    E Hartabilas
    I I Varthalitis
    I Messaritakis
    G Fountzilas
    V Georgoulias
    A Kotsakis
    British Journal of Cancer, 2017, 117 : 8 - 14
  • [24] Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer
    Masuda, N
    Matsui, K
    Negoro, S
    Takifuji, N
    Takeda, K
    Yana, T
    Kobayashi, M
    Hirashima, T
    Kusunoki, Y
    Ushijima, S
    Kawase, I
    Tada, T
    Sawaguchi, H
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3329 - 3334
  • [25] Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer - A Hellenic Cooperative Oncology Group Study
    Samantas, E
    Kalofonos, H
    Linardou, H
    Nicolaides, C
    Mylonakis, N
    Fountzilas, G
    Kosmidis, P
    Skarlos, D
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1395 - 1397
  • [26] Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer
    Bilgi, O.
    Karagoz, B.
    Alacacioglu, A.
    Ozgun, A.
    Tuncel, T.
    Gokhan-Kandemir, E.
    JOURNAL OF BUON, 2010, 15 (02): : 395 - 395
  • [27] A phase II study of paclitaxel (P) and carboplatin (C) as second-line treatment in patients (PTS) with small-cell lung cancer (SCLC)
    Agelaki, S
    Agelidou, M
    Blazogiannakis, G
    Tsiafaki, X
    Palamidas, T
    Kouroussis, C
    Kakolyris, S
    Malliotakis, C
    Samonis, G
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S258 - S259
  • [28] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Venepalli, N. K.
    Hutchison, A. S.
    Carbone, D. P.
    Johnson, D. H.
    Keedy, V. L.
    Pao, W.
    Sandler, A.
    Horn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Lovly, Christine Marie
    Li, Chung-I
    Hutchison, Anne Smith
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Pao, William
    Sandler, Alan
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Combination of docetaxel and irinotecan as a second-line treatment of metastatic gastric cancer: a phase II study
    Abdelaziz, Reham
    Hegazy, Amira
    Sohaib, Ahmed
    ONCOLOGY IN CLINICAL PRACTICE, 2025,
12345